Also Included In: Neurology / Neuroscience; Radiology / Nuclear Medicine
Article Date: 13 Dec 2011 - 1:00 PST
email to a friend 
printer friendly 
opinions 
Glioblastoma multiforme (GBM) is the most common and lethal of all human brain tumors that originate in the brain.
For most patients, treatment involves surgery followed by both radiation therapy and chemotherapy with temozolomide. However, many GBMs are resistant to the effects of temozolomide.
A team of researchers led by Sameer Agnihotri, at the University of Toronto, Toronto, has now determined that the protein APNG can contribute to GBM resistance to the effects of temozolomide. Importantly, high levels of expression of APNG in the nucleus of ressected tumor cells correlated with poorer overall survival compared with patients lacking APNG expression. Agnihotri, and colleagues therefore suggest that monitoring APNG levels could provide insight into whether or not a patient with GBM will respond to temozolomide, although this awaits confirmation in predictive and prospective studies.
TITLE: Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.Visit our cancer / oncology section for the latest news on this subject. Please use one of the following formats to cite this article in your essay, paper or report:
MLA
13 Dec. 2011.
Please note: If no author information is provided, the source is cited instead.
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
